Literature DB >> 17550060

Anti-HIV drugs.

E De Clercq1.   

Abstract

There are, at present, 22 compounds which have been formally approved (by the US Food and Drug Administration) for the treatment of HIV infections (AIDS). According to their point of intervention with the HIV replicative cycle, these compounds can be classified in 5 categories: (1) NRTIs (nucleoside reverse transcriptase inhibitors): azidothymidine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine; (2) NtRTIs (nucleotide reverse transcriptase inhibitors): tenofovir, administered as its oral prodrug form TDF (tenofovir disoproxil fumarate); (3) NNRTIs (non-nucleoside reverse transcriptase inhibitors): nevirapine, delavirdine and efavirenz; (4) PIs (HIV protease inhibitors): saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir; and (5) FIs (fusion inhibitors): enfuvirtide. Starting from the drugs which are currently available for the treatment of AIDS, numerous combinations could be envisaged. Drug combinations are, in principle, aimed at obtaining synergism between the compounds (reasonably expected if they act by different mechanisms), while reducing the likelihood for drug resistance development. Such anti-HIV drug combination regimes were initiated about 10 years ago and have been generally referred to as HAART (for highly active antiretroviral therapy). While HAART originally consisted of a pill burden of twenty (or more) pills per day, this has been gradually diminished over the past few years, and, since July 2006, a all-in-one pill (Atripla) has become available, which contains three anti-HIV drugs (tenofovir disoproxil fumarate, emtricitabine and efavirenz) to be taken as a single pill only once daily. Given the information that has been acquired on the therapeutic use (efficacy, safety) of tenofovir disoproxil fumarate over the past five years, it would now seem mandatory to further consider the prophylactic use of TDF [and its combination with emtricitabine (Truvada) and/or Atripla], as a single daily pill to prevent HIV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17550060

Source DB:  PubMed          Journal:  Verh K Acad Geneeskd Belg        ISSN: 0302-6469


  13 in total

1.  The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.

Authors:  K A Kirby; K Singh; E Michailidis; B Marchand; E N Kodama; N Ashida; H Mitsuya; M A Parniak; S G Sarafianos
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2011-02-12       Impact factor: 1.770

Review 2.  A transient kinetic approach to investigate nucleoside inhibitors of mitochondrial DNA polymerase gamma.

Authors:  Karen S Anderson
Journal:  Methods       Date:  2010-05-31       Impact factor: 3.608

3.  Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir.

Authors:  Klára Grantz Sasková; Milan Kozísek; Martin Lepsík; Jirí Brynda; Pavlína Rezácová; Jana Václavíková; Ron M Kagan; Ladislav Machala; Jan Konvalinka
Journal:  Protein Sci       Date:  2008-06-17       Impact factor: 6.725

4.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

5.  Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.

Authors:  Klára Grantz Sasková; Milan Kozísek; Pavlína Rezácová; Jirí Brynda; Tatyana Yashina; Ron M Kagan; Jan Konvalinka
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

6.  Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region.

Authors:  Milan Kozísek; Klára Grantz Sasková; Pavlína Rezácová; Jirí Brynda; Noortje M van Maarseveen; Dorien De Jong; Charles A Boucher; Ron M Kagan; Monique Nijhuis; Jan Konvalinka
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

7.  Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.

Authors:  Karen A Kirby; Eleftherios Michailidis; Tracy L Fetterly; Musetta A Steinbach; Kamalendra Singh; Bruno Marchand; Maxwell D Leslie; Ariel N Hagedorn; Eiichi N Kodama; Victor E Marquez; Stephen H Hughes; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

8.  4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.

Authors:  Eleftherios Michailidis; Andrew D Huber; Emily M Ryan; Yee T Ong; Maxwell D Leslie; Kayla B Matzek; Kamalendra Singh; Bruno Marchand; Ariel N Hagedorn; Karen A Kirby; Lisa C Rohan; Eiichi N Kodama; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

9.  High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.

Authors:  Christopher Nyakutira; Daniel Röshammar; Emmanuel Chigutsa; Prosper Chonzi; Michael Ashton; Charles Nhachi; Collen Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2007-12-05       Impact factor: 2.953

10.  The treatment of chronic hepatitis B: Focus on adefovir-like antivirals.

Authors:  Hans Ludger Tillmann
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.